Related references
Note: Only part of the references are listed.Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors
Chooi Peng Lee et al.
ONCOLOGIST (2015)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck et al.
LANCET ONCOLOGY (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis
Lutz Wollin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
Bercin Kutluk Cenik et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Pharmacokinetics, Distribution, and Metabolism of [14C]Sunitinib in Rats, Monkeys, and Humans
Bill Speed et al.
DRUG METABOLISM AND DISPOSITION (2012)
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
G. Bousquet et al.
BRITISH JOURNAL OF CANCER (2011)
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors Focus on Pyrimidines, Pyridines and Pyrroles
Paola Di Gion et al.
CLINICAL PHARMACOKINETICS (2011)
Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers
Peter Stopfer et al.
XENOBIOTICA (2011)
New antiangiogenics in non-small cell lung cancer treatment: Vargatef (TM) (BIBF 1120) and beyond
Bruno Gori et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2011)
Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
Klaus Mross et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
Peter M. Ellis et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Isamu Okamoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Clinical pharmacokinetics of tyrosine kinase inhibitors
Nielka P. van Erp et al.
CANCER TREATMENT REVIEWS (2009)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Share Paper
